Denali Therapeutics Inc. (DNLI) Stock Split, History Data
Working capital analysis
In terms of working capital, Denali Therapeutics Inc. maintains a healthy position.
The total current assets of the company are valued at $1064137000.
This represents a growth rate of -22.457% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $127106000, exhibiting a growth rate of -41.706% year-on-year.
The receivables, another significant portion of the current assets, are valued at $2700000.
The year-on-year growth rate for receivables is -46.000%.
The inventory, which forms a critical part of the assets, is valued at $1.
This represents a healthy year-on-year growth of -100.000%
On the liabilities side, the company's current liabilities total $77982000.
This reflects a growth rate of -78.572% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
127.11
218.04
293.48
507.14
79.45
77.12
Receavebles
2.70
5.00
1.23
5.67
0.00
8.55
Inventory
0.00
5
0.00
0.00
0.00
8.55
Other
26.93
36.10
30.60
20.28
14.68
16.54
Total Current Assets
1064.14
1372.32
897.23
1495.65
430.03
480.84
Acc Payable
9.48
2.79
4.78
1.07
2.59
1.89
Short Term Debt
7.26
7.32
5.45
4.69
3.67
19.09
Other Current Liab
61.24
63.76
47.71
42.45
20.35
0.38
Current Liabilities
77.98
363.92
378.25
71.70
45.34
32.79
Capital Structure
When examining the capital structure of Denali Therapeutics Inc., it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $1153917000.
When juxtaposed with the previous year, this marks a growth rate of -20.978%, showcasing the company's ability to steadily grow its asset base.
Turning to liabilities, the company has total liabilities amounting to $122963000.
Compared to the prior year, this reflects a growth rate of -70.570%.
The long-term debt forms a sizable part of these liabilities, coming in at $44981000.
Over the last year, the long-term debt has grown by -15.181%.
On the asset side, the cash and equivalent reserves are worth $127106000.
The year-on-year growth of these reserves is -41.706%.
The company's common stock, another important asset, holds a value of $1711000, growing at a rate of 1.483% from the previous year.
Finally, the company's retained earnings stand at $-1116211000, marking a growth rate of 14.956% year-over-year.
These earnings represent the profits that Denali Therapeutics Inc. has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$1,153.92
Total liabilities
$122,963,000.00
Long term debt
$44.98
Cash and eqv
$127,106,000.00
Goodwill
$0.00
Retained earnings
-$1,116,211,000.00
Common stock
$2.69
Enterprise Value
-$12.37
Net earnings per share (EPS)
Denali Therapeutics Inc. has an EPS of $-1.04, which signifies the profit allocated per share of common stock. With a growth rate of 59.690% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
